Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sorrento Therapeutics Inc (OQ:SRNE)

Business Focus: Bio Therapeutic Drugs

May 29, 2020 03:10 pm ET
Shareholder Alert: Robbins LLP Announces Sorrento Therapeutics, Inc. (SRNE) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 15, 2020, and May 22, 2020. Sorrento is a clinical stage biopharma company that develops
May 29, 2020 11:40 am ET
(SRNE) Lead Plaintiff Alert: Does Your Loss Exceed $100,000 In Sorrento Therapeutics? Contact Johnson Fistel, LLP
SAN DIEGO, May 29, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has been filed on behalf of all those who purchased or otherwise, acquired Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE) between May 15, 2020 and May 22, 2020, inclusive (the "Class Period"). ...
May 28, 2020 04:39 pm ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contac
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc. (“Sorrento” or “the Company”) (NASDAQ:
May 28, 2020 02:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Sorrento Therapeutics, Inc. (SRNE) Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ:
May 28, 2020 01:00 pm ET
SRNE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Sorrento Therapeutics, Inc and Encourages Investors to Contact the Firm
NEW YORK, May 28, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sorrento Therapeutics, Inc. ("Sorrento" or "the Company") (NASDAQ: SRNE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Sorrento securities between May 15, 2020 through May 22, 2020, inclusive (the ''Class Period''). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/srne.  ...
May 28, 2020 11:00 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE)
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ:
May 28, 2020 09:21 am ET
(SRNE) Alert: Johnson Fistel Investigates Sorrento Therapeutics; Investors Suffering Losses Encouraged to Contact Firm
SAN DIEGO, May 28, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE). ...
May 27, 2020 09:05 pm ET
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE)
The Law Offices of Frank R. Cruz announces an investigation on behalf of Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ:
May 27, 2020 07:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Sorrento Therapeutics, Inc. (SRNE) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased of Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE) common stock between May 15, 2020 and May 22, 2020, inclusive (the “Class Period”). Sorrento investors have until
May 27, 2020 06:00 pm ET
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of Sorrento Therapeutics, Inc. (SRNE) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, today announced that it has commenced an investigation on behalf of Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ:
May 27, 2020 04:46 pm ET
Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Sorrento Therapeutics, Inc. (SRNE)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) (NASDAQ: SRNE) and...
May 27, 2020 03:10 pm ET
Portnoy Law: Sorrento Therapeutics, Inc. Investors have until July 27, 2020 to file Lead Plaintiff Motion
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) investors that acquired Sorrento securities (NASDAQ: SRNE) between May 15, 2020 and May 22,...
May 27, 2020 02:39 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sorrento Therapeutics, Inc. (SRNE) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE) investors concerning the Company and its officers’ possible violations of federal securities laws.
May 27, 2020 01:45 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sorrento Therapeutics, Inc. (“Sorrento” or “the Company”) (NASDAQ:
May 27, 2020 12:41 pm ET
SORRENTO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Sorrento Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Sorrento Therapeutics, Inc. (NASDAQ: SRNE) common stock between May 15, 2020 and May 22, 2020 (the “Class Period”). Investors have until July 27, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
May 26, 2020 04:34 pm ET
SRNE INVESTOR ALERT: Kirby McInerney LLP Announces That it has Filed a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors to Contact the Firm Before July 27
The law firm of Kirby McInerney LLP announces that it has filed a class action lawsuit in the U.S. District Court for the Southern District of California on behalf of those who acquired Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”)...
May 26, 2020 09:31 am ET
Thinking about trading stocks or options in Splunk, Carnival Corp, Sorrento Therapeutics, Boeing, or Eldorado Resorts?
NEW YORK, May 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPLK, CCL, SRNE, BA, and ERI....
May 26, 2020 09:00 am ET
Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129, a CD38-targeting antibody drug...
May 22, 2020 05:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE
Pomerantz LLP is investigating claims on behalf of investors of Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) (NASDAQ: SRNE). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
May 21, 2020 07:00 am ET
Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of China. The final...
May 20, 2020 11:00 am ET
Thinking about buying stock in Kitov Pharma, Sorrento Therapeutics, Seanergy Maritime Holdings, Moderna, or MGM Resorts?
NEW YORK, May 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KTOV, SRNE, SHIP, MRNA, and MGM....
May 18, 2020 09:31 am ET
Thinking about buying stock in Sorrento Therapeutics, Chesapeake Energy Corp, Trevena, Delta Air Lines, or Royal Caribbean Cruises?
NEW YORK, May 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, CHK, TRVN, DAL, and RCL....
May 15, 2020 11:00 am ET
STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies
SAN DIEGO, May 15, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration....
May 15, 2020 10:45 am ET
Thinking about buying stock in Sorrento Therapeutics, Cassava Sciences, Diffusion Pharma, Onconova Therapeutics, or Bridgeline Digital?
NEW YORK, May 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, SAVA, DFFN, ONTX, and BLIN....
May 13, 2020 09:31 am ET
Thinking about buying stock in Capricor Therapeutics, Waitr, Takeda Pharmaceutical, Sorrento Therapeutics, or Inovio Pharmaceuticals?
NEW YORK, May 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, WTRH, TAK, SRNE, and INO....
May 08, 2020 09:20 am ET
Sorrento And Mount Sinai Health System To Jointly Develop COVI-SHIELD™ Antibody Therapy Targeting SARS-CoV-2 Infection (COVID-19)
SAN DIEGO, May 8, 2020 /PRNewswire/ --Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Mount Sinai Health System ("Mount Sinai") have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD™) to potentially treat COVID-19....
Apr 02, 2020 12:33 pm ET
SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative allogeneic...
Mar 31, 2020 02:01 pm ET
SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product...
Mar 25, 2020 10:00 am ET
Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA’s Center for Biologics Evaluation and Research under...
Mar 24, 2020 09:32 am ET
SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited (Hong Kong Stock Exchange: 2181HK, “Mabpharm”), for the...
Mar 23, 2020 09:00 am ET
SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19
In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm Therapeutics Inc. (SmartPharm) today announced a research and development collaboration to develop a...
Mar 20, 2020 07:00 am ET
SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has produced a preclinical batch of the STI-4398 (COVIDTRAP) protein to immediately commence testing its neutralization and blocking activity in preventing SARS-CoV-2 virus from...
Feb 27, 2020 03:30 pm ET
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced that an interim analysis of an ongoing Phase 1b study of resiniferatoxin (RTX) administered via epidural route in patients with intractable cancer pain has generated positive data....
Feb 27, 2020 06:00 am ET
Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will present at the 9th Annual LEERINK Partners Global Healthcare Conference (Lotte New York Palace Hotel, New York) on Thursday Feb 27 at...
Feb 21, 2020 09:15 am ET
Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference (Lotte New York Palace Hotel, New York) on Thursday Feb 27 at 11:00-11:25 AM (Presentation Room...
Jan 29, 2020 07:00 am ET
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initated a clinical and manufacturing collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative...
Jan 27, 2020 07:00 am ET
Sorrento Board Rejects Latest Acquisition Proposal
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that, after reviewing the latest acquisition proposal in consultation with its advisors, Sorrento’s Board of Directors (the “Board”) determined that the offer significantly...
Jan 27, 2020 07:00 am ET
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced the positive results of multiple resiniferatoxin (RTX) pre-pivotal (phase 1b/2) clinical studies, which will be presented at two upcoming prestigious pain conferences....
Jan 10, 2020 07:00 am ET
Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento” or the “Company”), announced today that on January 9, 2020, it received a non-binding proposal from a private equity fund to acquire a majority or all of the issued and outstanding shares of the...
Jan 06, 2020 07:00 am ET
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab biosimilar antibody in China. Sorrento plans to file a Biologics License Application (BLA) for the...
Dec 16, 2019 07:00 am ET
Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors. Dr. Smith is a business leader, entrepreneur, medical doctor, author and philanthropist who has held...
Dec 09, 2019 07:00 am ET
Sorrento Announces New Board Member
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Mr. Edgar Lee has been appointed to its Board of Directors. Mr. Lee is currently a Managing Director at Oaktree Capital Management. Mr. Lee founded and was the portfolio...
Nov 25, 2019 07:00 am ET
Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento" or the “Company”), confirmed today that on November 23, 2019, it received an unsolicited, non-binding term sheet proposal submitted by two biopharmaceutical companies, to acquire all of the...
Nov 12, 2019 07:05 am ET
 Sorrento CEO to Present at Upcoming Investor Conferences
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in upcoming investor conferences in the 4th quarter 2019. Dr. Ji will provide a corporate overview and business update...
Nov 06, 2019 07:37 pm ET
 Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will participate in upcoming industry conferences in the 4th quarter 2019. Sorrento will provide...
Oct 15, 2019 10:36 pm ET
Los Angeles Court Rejects Patrick Soon-Shiong’s Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt to allow him and his company, NantPharma, to avoid the billion-dollar fraud and breach of...
Oct 09, 2019 10:35 am ET
Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the closing of...
Oct 07, 2019 02:35 pm ET
Sorrento Therapeutics Announces $25 Million Registered Direct Offering
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced that it has...
Sep 30, 2019 07:00 am ET
Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak
Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in May of this year. Dr. Whitcup is founder and Chief Executive Officer of Akrivista, LLC and Whitecap...
Sep 23, 2019 07:00 am ET
Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission...
Sep 06, 2019 09:50 am ET
CBD Products Continue to Reap the Benefits of Legalization
NEW YORK, Sept. 6, 2019 /PRNewswire/ -- The hemp industry has grown significantly over recent years as cannabis legalization has become more prominent. Notably, with the passage of the U.S. Farm Bill, the industry is primed to witness even further substantial growth. Historically, hemp has been used for centuries because of its multifarious nature. The plant was predominantly used as either an herbal medicinal treatment or as a resource for manufacturing purposes. However, now the U.S. Farm bill essentially legalized all products related to hemp, which includes hemp-derived CBD goods. Moreov...
Sep 05, 2019 08:00 am ET
Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment conferences in September 2019. Dr. Ji will provide corporate updates to investors, focusing on the...
Jul 02, 2019 12:40 pm ET
Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the closing of...
Jun 28, 2019 08:37 am ET
Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the pricing of...
Jun 28, 2019 06:00 am ET
Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced that it intends...
Jun 19, 2019 07:00 am ET
Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy 
T cell therapy with IND submission targeted for second half of 2019○ CD38 Antibody-Drug Conjugate (“ADC”) IND to be submitted in Q4 2019○ CD38-directed immunotherapies demonstrate potent cytotoxicity in preclinical models and against...
Jun 19, 2019 07:00 am ET
Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the Phase 1b study currently in progress has generated positive data and met the day 84 goals set for the resiniferatoxin (RTX) program to advance the investigational drug...
Jun 14, 2019 07:00 am ET
Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces today that senior management will be presenting in the upcoming JMP Life Sciences Conference in New York City. Sorrento Therapeutics Speaker: Dr. Henry Ji (Chairman and CEO)...
Jun 12, 2019 07:00 am ET
Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company
Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its majority-owned subsidiary, Scilex Holding Company. No decisions have been taken at this point on the...
Jun 10, 2019 07:00 am ET
Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of...
Jun 05, 2019 07:00 am ET
Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration
Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announces the completion of post-merger integration. Following the merger with Semnur Pharmaceuticals, Inc. in March 2019, and...
Jun 04, 2019 07:00 am ET
Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships
Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd. (“Shenzhen Yunma”), with LifeTech Scientific Co., Ltd. (LifeTech, HKSE: 1302) to commercialize...
May 21, 2019 06:25 pm ET
Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB Riley Investor Conference and meeting with individual investors. Date/Time: May 22nd, 2019 at...
Apr 16, 2019 09:00 am ET
Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that it has established a new business unit to focus on the market potential for its innovative water soluble cannabidiol (CBD) formulation technology. Cannabidiol (CBD) has...
Apr 15, 2019 04:00 am ET
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology...
Apr 10, 2019 09:00 am ET
Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study aimed at exploring potential benefits of resiniferatoxin in controlling neuro-inflammatory...
Apr 08, 2019 08:20 am ET
Market Trends Toward New Normal in NIKE, Harley-Davidson, Knowles, Sorrento Therapeutics, OptiNose, and Columbia Sportswear — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of NIKE, Inc. (NYSE:NKE), Harley-Davidson, Inc. (NYSE:HOG), Knowles...
Mar 26, 2019 08:30 am ET
Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program
Scilex Holdings, Inc. (“Scilex”), a majority owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), today announced results of a Phase 2 trial (SP-102-03), an open-label, single-arm, pharmacodynamic and safety study of repeat...
Mar 22, 2019 07:00 am ET
Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals Inc. (Scilex) has closed a transaction to merge with Mountain View, California, based Semnur Pharmaceuticals, Inc. (Semnur) to form...
Mar 11, 2019 07:00 am ET
Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human...
Feb 25, 2019 07:00 am ET
Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that senior management will provide a corporate overview at the upcoming SVB/Leerink Global Healthcare Conference, and the Oppenheimer & Co. 29th Annual Healthcare Conference,...
Feb 12, 2019 07:00 am ET
Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program
Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed a private equity financing of $40 million USD at a pre-money valuation of $95...
Jan 31, 2019 08:20 am ET
New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie's Bargain Outlet, Covanta Holding, and Sorrento Therapeutics — Factors of Influence, Major Initiatives and Sustained Prod
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tapestry, Inc. (NYSE:TPR), Fidelity National Information Services, Inc....
Jan 22, 2019 07:00 am ET
Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials T
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from osteoarthritis in the knee (intra-articular...
Jan 14, 2019 07:00 am ET
Scilex Announces Addition of ZTlido® to Express Scripts National Formularies
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30...
Jan 14, 2019 07:00 am ET
Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by nearly 100M U.S. insured lives1.  ZTLIDO is indicated for relief...
Jan 04, 2019 07:00 am ET
Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that Dr. Henry Ji, Chairman and CEO, will participate in the East/West CEO conference in San Francisco on January 5th, 2019 at 2:00PM PST at the Four Seasons Hotel San Francisco...
Nov 08, 2018 07:00 am ET
Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million
Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150 million. The financing is being provided by funds and accounts managed by Oaktree Capital...
Nov 06, 2018 08:01 am ET
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento") announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life...
Nov 01, 2018 07:00 am ET
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple...
Oct 25, 2018 08:10 am ET
Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook — Fundamental Analysis, Calcu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sorrento Therapeutics, Inc. (NASDAQ:SRNE), Hurco Companies, Inc....
Oct 01, 2018 08:00 am ET
Scilex Announces the Availability of ZTlido™
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), announced that ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is now commercially available.  ZTLIDO will be shipped to wholesalers and...
Sep 27, 2018 06:09 pm ET
Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018
Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric, biopharmaceutical company developing new therapies today announced that Henry Ji Ph.D,, Chairman, President and CEO will  present at the Leerink Partners...
Sep 19, 2018 08:00 am ET
Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is...
Sep 10, 2018 04:00 am ET
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), closed a debt financing with leading global institutional investors for aggregate gross proceeds to...
Sep 07, 2018 12:24 pm ET
Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation
SAN DIEGO, Sept. 7, 2018 /PRNewswire/ -- Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced data showing ZTlido™ (lidocaine topical system) 1.8% (ZTlido) demonstrated a statistically significant improved adhesion profile compared to Lidoderm® (lidocaine patch 5%) (Lidoderm) and Versatis® (Medicated Plaster 5%) (Versatis)1. In a separate study, ZTlido was found to be bioequivalent to Lidoderm2. The presentation of results at PAINWeek 2018 in Las Vegas, September 4-8, followed U.S. Food and Drug Administration (FDA) appr...
Sep 04, 2018 08:30 am ET
Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movemen
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation (NYSE:BRC), Akari Therapeutics PLC (NASDAQ:AKTX), MTGE...
Sep 02, 2018 01:19 pm ET
Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in upcoming investment healthcare conferences. FB Riley Healthcare Conference (Sept 4th)NY Marriot East Side. 525...
Aug 13, 2018 04:00 am ET
1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from...
Jul 03, 2018 09:30 am ET
Sorrento Acquires the Sofusa™ Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento") announced today that it acquired the Sofusa™ lymphatic delivery technology platform from Kimberly-Clark Corporation  for targeted biopharmaceuticals, particularly, the immune checkpoint...
Jun 14, 2018 04:42 pm ET
Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Dear Sorrento Stockholders, It is with pride that I issue this mid-year update letter to our shareholders. Since the beginning of 2018, we have been working diligently on the implementation of our current...
May 11, 2018 08:30 am ET
Consolidated Research: 2018 Summary Expectations for Sunstone Hotel Investors, Plains All American Pipeline, Sorrento Therapeutics, TD Ameritrade Holding, Meritor, and DXC Technology — Fundamental Ana
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunstone Hotel Investors, Inc. (NYSE:SHO), Plains All American Pipeline,...
Apr 23, 2018 08:00 am ET
Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”
SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, has been invited to participate as an expert panelist at the Fourth International Vatican Conference, in...
Apr 05, 2018 02:53 pm ET
Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916)
SAN DIEGO, April 05, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) and Celularity Inc announced today that the companies have started screening patients for its leading CD38 chimeric antigen receptor (CAR) T cell therapy drug development program,...
Apr 04, 2018 05:46 pm ET
Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that it will present at the H.C. Wainwright Global Lifesciences conference on 04/09/18 at 4:15 PM GMT+1 Time (8:15 AM PDT/11:15 AM EDT),...
Mar 28, 2018 07:28 pm ET
Sorrento Therapeutics Chairman/CEO update to stockholders
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
Mar 27, 2018 08:00 am ET
Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that it has entered into a securities purchase agreement to sell $120.5 million of unsecured convertible notes in a private placement to certain...
Mar 20, 2018 11:03 pm ET
Sorrento Therapeutics CEO Dr Ji to Present at Needham 17th Annual Healthcare Conference on 03/27/18
SAN DIEGO, March 20, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that Dr Ji will present at the Needham 17th Annual Healthcare Conference in NYC on March 27th 2018 at 5PM EDT (Westin Grand...
Mar 19, 2018 08:00 am ET
Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento") announced today that it appointed Mr Jiong Shao as Executive Vice President and Chief Financial Officer.
Mar 14, 2018 10:08 pm ET
Sorrento Therapeutics to Present at the 28th Annual Oppenheimer Conference (NY) on 03/20/18
SAN DIEGO, March 14, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that it will present at the Oppenheimer 28th annual conference on 03/20/18 at 2:45 PM EST (Westin NY Grand Central).
Mar 14, 2018 05:48 pm ET
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) investors concerning the Company and its directors’ and officers’ possible violations of state laws.
Mar 08, 2018 06:16 pm ET
 Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th Annual Growth Stock Conference on 03/12/18
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that it will present at Roth Capital Partners 30th annual growth stock conference on 03/12/18 at 1:30 PM (Laguna Niguel Ritz Carlton, Salon...
Mar 05, 2018 08:00 am ET
Feb 28, 2018 02:12 pm ET
Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido™ (lidocaine topical system) 1.8% for PHN Pain
ZTlido™ Uses Novel Technology Demonstrating 12-Hour Wear for Efficient Lidocaine Delivery, Even During Exercise
Feb 27, 2018 12:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE
NEW YORK, Feb. 27, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ:  SRNE).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Feb 27, 2018 12:41 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sorrento Therapeutics, Inc. (SRNE)
NEW YORK, Feb. 27, 2018 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") (NASDAQ: SRNE). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/srne....
Feb 15, 2018 11:00 am ET
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration
WARREN, N.J., Feb. 15, 2018 /PRNewswire/ -- Celularity has been created through the contribution and acquisition of extensive intellectual property, clinical-stage assets, basic and clinical research, and product development expertise including: ...
Feb 08, 2018 08:20 am ET
Investor Expectations to Drive Momentum within Mettler-Toledo International, Party City Holdco, Old Dominion Freight Line, Sun Hydraulics, Sorrento Therapeutics, and Lexicon Pharmaceuticals — Discover
NEW YORK, Feb. 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mettler-Toledo International, Inc. (NYSE:MTD), Party City...
Feb 05, 2018 08:01 am ET
Sorrento Therapeutics, Inc. Chairman/CEO letter to stockholders
SAN DIEGO, Feb. 05, 2018 (GLOBE NEWSWIRE) --
Feb 05, 2018 08:00 am ET
Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea
SEOUL, South Korea and SAN DIEGO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Effective February 5th, 2018, Yuhan Corporation (KRX:000100.KS) (Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq:SRNE) (Sorrento) announce that the South Korean Ministry of Food and Drug Safety (MFDS)...
Feb 02, 2018 08:00 am ET
Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18
SAN DIEGO, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that it will present at LEERINK Partners 7th Annual Global Healthcare Conference (Lotte New York Palace Hotel, New York) on Thu, Feb 15...
Jan 29, 2018 08:06 am ET
China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody
HONG KONG and SAN DIEGO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Effective January 29th, 2018, Lee’s Pharm and Sorrento Therapeutics announce that the Chinese authorities have approved China Oncology Focus Limited (COF, an affiliate of Lee’s Pharmaceutical Holdings...
Jan 24, 2018 08:00 am ET
Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility
SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today the expansion of its Good Manufacturing Practices (GMP) CAR-T manufacturing capacity, with an exclusive agreement to operate the “Cellular Immunotherapy and Gene Therapy...
Jan 22, 2018 08:00 am ET
Sorrento Therapeutics to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference on 01/29/18
SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that it will present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida – on...
Jan 02, 2018 08:00 am ET
Sorrento Therapeutics to Present Potential “Game-Changer” Non-Viral CAR-T Technology for Autologous and Allogeneic (off-the-shelf) CAR-T Therapies
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) (NASDAQ:SRNE) announced today that Dr. Henry Ji, Chairman & CEO of Sorrento, will share recent Sorrento developments and Company information in a panel...
Nov 17, 2017 08:30 am ET
New Research Coverage Highlights Principal Financial Group, Dunkin' Brands Group, Dell Technologies, Paramount Group, Sorrento Therapeutics, and Lexicon Pharmaceuticals — Consolidated Revenues, Compan
NEW YORK, Nov. 17, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Principal Financial Group Inc (NYSE:PFG), Dunkin'...
Nov 14, 2017 09:00 am ET
Scilex Pharmaceuticals, Sorrento Therapeutics' Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido™
SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that Scilex Pharmaceuticals Inc. ("Scilex"), a majority-owned subsidiary of Sorrento, filed the European Marketing Authorization Application (MAA) for its lead product candidate, ZTlido™ (lidocaine medicated plaster 1.8%), through a hybrid regulatory pathway with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK)....
Oct 25, 2017 08:00 am ET
Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer
Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious cutaneous oncology indications, announced...
Oct 02, 2017 09:00 am ET
Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors
SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Effective September 26, 2017, the Board of Directors (the "Board") of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) appointed each of Dorman Followwill and David Lemus as an independent director of the Company. ...
Sep 19, 2017 09:00 am ET
Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET)
SAN DIEGO, Sept. 19, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the Cantor Global Healthcare Conference, taking place in New York City (Intercontinental NY Barclay Hotel)....
Sep 12, 2017 07:00 am ET
FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018
SAN DIEGO, Sept. 12, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration ("FDA") acknowledgement of receipt of its recently resubmitted New Drug Application ("NDA") for ZTlido™ (lidocaine patch 1.8%) which has been considered a complete, class 2 response to the prior action letter....
Sep 08, 2017 05:03 pm ET
Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET)
SAN DIEGO, Sept. 8, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the 19th Rodman and Renshaw global investment conference, taking place in New York City at the Lotte New York Palace Hotel....
Aug 29, 2017 07:00 am ET
Sorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA comments related to the initial NDA submission for its lead product candidate, ZTlido™ (lidocaine patch 1.8%).  ...
Aug 21, 2017 06:21 pm ET
Sorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies
SAN DIEGO, Aug. 21, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the transactions contemplated by the Contribution Agreement it entered with Celularity, Inc. ("Celularity") has closed.  Sorrento previously announced that it together with its subsidiary, TNK Therapeutics, Inc. ("TNK"), had entered into a definitive agreement ("Contribution Agreement") to offer certain immuno-oncology and cellular therapy intellectual property and assets to Celularity, a company being formed and run by former Celgene Cellular Therapeutics CEO, Robert Hariri, MD/PhD...
Aug 21, 2017 05:22 pm ET
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform
---New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration ...
Aug 21, 2017 05:22 pm ET
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform
---New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration ...
Jun 29, 2017 01:22 pm ET
Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
SAN DIEGO, June 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug Application (IND) for Resiniferatoxin (RTX), a non-opioid, TRPV1 agonist that selectively targets afferent nerve activation involved in chronic pain states. Sorrento intends to promptly initiate a multicenter, Phase 1b clinical trial of RTX administered by epidural injection for the treatment of intractable pain associated with cancer. RTX has been granted FDA Orphan Drug Status ...
Jun 26, 2017 08:00 am ET
Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102
LOS ALTOS, Calif., June 26, 2017 /PRNewswire/ -- Semnur Pharmaceuticals, Inc. ("Semnur") today announced successful Phase 1 / 2 pharmacokinetic bridging trial of the lead product SP-102.  The trial was conducted in the patients with radicular pain, achieved its primary pharmacokinetic endpoint, and also demonstrated that a single epidural injection of SP-102 can lead to a sustained analgesic effect lasting one month....
Jun 14, 2017 03:29 pm ET
Sorrento Therapeutics Announces Dismissal Of Lawsuits
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Sorrento Therapeutics (NASDAQ: SRNE) announced today the dismissal of all claims against Sorrento and its Directors contained in the lawsuits brought by Wildcat Liquid Alpha, LLC....
Jun 14, 2017 10:00 am ET
Sorrento Therapeutics' Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido™
SAN DIEGO, June 14, 2017 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its lead investigational product, ZTlido™ (lidocaine medicated plaster 1.8%), has demonstrated superior adhesion versus the EU reference product Versatis® (medicated plaster 5%) during a recently completed comparative adhesion performance study. The study was performed to support the market authorization application (MAA) for ZTlido™ in the EU. These data complement a previous clinical adhesion study performed to support ...
Jun 13, 2017 10:00 am ET
Sorrento Therapeutics Contributes to the Formation of Celularity, Inc.
SAN DIEGO, June 13, 2017 /PRNewswire/ -- Sorrento Therapeutics (NASDAQ: SRNE) announced today that it together with its subsidiary, TNK Therapeutics, have executed a definitive agreement to contribute certain immuno-oncology and cellular therapy intellectual property and assets to Celularity, Inc., a company being formed and run by former Celgene Cellular Therapeutics CEO, Robert Hariri, MD/PhD. Celularity is assembling key assets from a growing number of companies in the cellular medicine arena. ...
May 04, 2017 10:41 am ET
Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business
SUZHOU, China, May 4, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), announced today that its subsidiary, Levena Biopharma Co., Ltd. ("Levena"), has completed construction and put into operation a 25,000 square foot Good Manufacturing Practice (GMP) manufacturing facility in Suzhou, China.  The facility will be fully dedicated to supporting Sorrento's antibody drug conjugate (ADC) pipeline and growing service business. ...
May 04, 2017 10:41 am ET
Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business
SUZHOU, China, May 4, 2017 /CNW/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), announced today that its subsidiary, Levena Biopharma Co., Ltd. ("Levena"), has completed construction and put into operation a 25,000 square foot Good Manufacturing Practice (GMP) manufacturing facility in Suzhou, China.  The facility will be fully dedicated to supporting Sorrento's antibody drug conjugate (ADC) pipeline and growing service business. ...
Apr 28, 2017 10:00 am ET
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
SAN DIEGO, April 28, 2017 /CNW/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today the closing of a transaction whereby its cellular therapy focused subsidiary, TNK Therapeutics, Inc. ("TNK"), has acquired Virttu Biologics Limited ("Virttu"). ...
Apr 28, 2017 10:00 am ET
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
SAN DIEGO, April 28, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today the closing of a transaction whereby its cellular therapy focused subsidiary, TNK Therapeutics, Inc. ("TNK"), has acquired Virttu Biologics Limited ("Virttu"). ...
Apr 19, 2017 05:05 pm ET
Sorrento Announces Closing of Public Offering of Common Stock
SAN DIEGO, April 19, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, today announced the closing of its previously announced underwritten public offering of 23,625,084 shares of its common stock at a public offering price of $2.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by Sorrento.  The net proceeds to Sorrento from this offering were approximately $43.5 million, afte...
Apr 13, 2017 10:58 am ET
Sorrento Announces Pricing of Public Offering of Common Stock
SAN DIEGO, April 13, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, today announced the pricing of its public offering of 23,625,084 shares of its common stock at a price to the public of $2.00 per share. In addition, Sorrento has granted the underwriters an option exercisable, in whole or in part, in the sole discretion of the underwriters, to purchase up to 3,543,763 additional shares, for a period of up to 30 days. All of the shar...
Apr 12, 2017 05:00 pm ET
Sorrento Announces Proposed Public Offering of Common Stock
SAN DIEGO, April 12, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Sorrento will grant the underwriter an option exercisable, in whole or in part, in the sole discretion of the underwriter, to purchase additional shares, for a period of up to 30 days. All of the shares will be offe...
Apr 03, 2017 02:25 pm ET
Sorrento Therapeutics anti-CEA CAR-T Demonstrates Promising Clinical Activity and Safety in Phase Ib Clinical Trial
SAN DIEGO, April 3, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), and its cellular therapy focused subsidiary, TNK Therapeutics, Inc. ("TNK"), announced today the results from the Hepatic ImmunoTherapy for Metastases-Selective Internal Radiation Therapy, or HITM-SIR (NCT02416466), Study, a Phase Ib single arm trial testing its anti-CEA CAR-T administered regionally by hepatic artery infusion (HAI) followed by selective internal radiation therapy (SIRT) in heavily pre-treated patients with CEA positive liver metastases.  This Phase Ib trial follows the Hep...
Mar 20, 2017 09:00 am ET
Sorrento and Wildcat Announce Resolution
SAN DIEGO, March 20, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (the "Company" or "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Wildcat Capital Management LLC ("Wildcat"), whose clients currently are major holders of the outstanding common stock of Sorrento, today jointly announced that they have reached a mutual understanding and resolution with respect to Wildcat's claims seeking inspection of documents related to the Company's private placement agreements announced by t...
Mar 20, 2017 09:00 am ET
Sorrento and Wildcat Announce Resolution
SAN DIEGO, March 20, 2017 /CNW/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (the "Company" or "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Wildcat Capital Management LLC ("Wildcat"), whose clients currently are major holders of the outstanding common stock of Sorrento, today jointly announced that they have reached a mutual understanding and resolution with respect to Wildcat's claims seeking inspection of documents related to the Company's private placement agreements announced by the Comp...
Mar 09, 2017 05:01 pm ET
Sorrento Therapeutics to Present at 29th Annual ROTH Conference
SAN DIEGO, March 9, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases announced today that it will participate in the 29th Annual ROTH Conference taking place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.  Sorrento will hold investor meetings and Kevin Herde, Executive Vice President, and Chief Financial Officer, will present at 1:30 p.m. Pacific Time on March 13, 2017....
Jan 23, 2017 09:00 am ET
The Life Sciences Report Examines the Inclusion of Sorrento Therapeutics on Streetwise Reports' 2017 Small-Cap Biotech Watchlist
The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.Included in this article is: Sorrento...
Jan 09, 2017 09:00 am ET
Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™
SAN DIEGO, Jan. 9, 2017 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study for its lead investigational product, ZTlido™ (lidocaine patch 1.8%), has met a primary endpoint establishing comparative pharmacokinetics and a secondary endpoint of bioequivalence as compared to the reference product in Europe, Versatis® (lidocaine medicated plaster 5%). ...
Dec 05, 2016 07:00 am ET
Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™
SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study for lead investigational product, ZTlido™ (lidocaine patch 1.8%), has met a primary endpoint establishing comparative pharmacokinetics and a secondary endpoint of bioequivalence for ZTlido as compared to the reference product, Lidoderm® (lidocaine patch 5.0%). ...
Dec 01, 2016 07:26 am ET
Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies
SAN DIEGO, Dec. 1, 2016 /PRNewswire/ -- TNK Therapeutics, Inc. ("TNK"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has provided an update on its lead chimeric antigen receptor (CAR) expressing T cells (CAR-T) programs for the treatment of hematological malignancies.  Adoptive immunotherapy utilizing CAR-T cells represents a promising new paradigm in the treatment of cancer.  Sorrento intends to present these findings at upcoming clinical conferences and in scientific publications....
Nov 28, 2016 05:56 pm ET
Sorrento Therapeutics, Inc. Secures $75 Million Loan Facility
SAN DIEGO, Nov. 28, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announces it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules") for a term loan of up to $75.0 million subject to funding in three tranches. The proceeds will be used for general corporate purposes allowing Sorrento the flexibility to consolidate core programs and more rapidly advance product opportunities in various t...
Nov 16, 2016 03:24 pm ET
Sorrento's TNK Therapeutics Subsidiary to Acquire Virttu Biologics
SAN DIEGO, Nov. 16, 2016 /PRNewswire/ -- TNK Therapeutics, Inc. ("TNK"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has entered into a binding term sheet to acquire Virttu Biologics Limited ("Virttu"). ...
Nov 14, 2016 06:00 am ET
Sorrento Therapeutics to Attend Jefferies and ROTH Investor Conferences
SAN DIEGO, Nov. 14, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, and other unmet medical needs, announced today that it will be presenting at the Jefferies London Healthcare Conference on November 16, 2016 and attending the ROTH Innovations in Oncology Corporate Access Day in New York City on November 17, 2016....
Nov 08, 2016 04:20 pm ET
Sorrento Therapeutics Closes Acquisition of Scilex
SAN DIEGO, Nov. 8, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento") and Scilex Pharmaceuticals Inc. ("SCILEX") announced today the closing of a transaction by which Sorrento acquired a majority of SCILEX.  Sorrento acquired approximately 72% of the outstanding common stock of SCILEX for a net purchase price of up to approximately $47.6 million, payable in a combination of cash and shares of Sorrento common stock.  Further, the U.S. Food & Drug Administration ("FDA") recently provided clear feedback related to the resubmission of the new drug application ("NDA")...
Sep 27, 2016 09:00 am ET
ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Submission of Two Major Technical Sections of a New Animal Drug Application
SAN DIEGO, Sept. 27, 2016 /PRNewswire/ -- ARK Animal Health, Inc. (ARK), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), has filed the Effectiveness and Target Animal Safety major technical sections of the New Animal Drug Application (NADA) for the control of pain associated with bone cancer in dogs.  ARK was granted a Minor Use/ Minor Species (MUMS) Drug Designation for ARK-001, a proprietary formulation containing the active ingredient Resiniferatoxin (also known as RTX) in June 2015.  Under the MUMS designation, ARK seeks the conditional approval of RTX and plans to ...
Sep 13, 2016 09:00 am ET
Sorrento Appoints Miranda Toledano As Executive Vice President of Corporate Development, and President of LA Cell
SAN DIEGO, Sept. 13, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today announced that Miranda Toledano has been appointed Executive Vice President of Corporate Development of Sorrento and President of LA Cell, Sorrento's Joint Venture with City of Hope....
Aug 30, 2016 05:01 pm ET
Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City
SAN DIEGO, Aug. 30, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, and other unmet medical needs, announced today that it will be presenting at two upcoming conferences in New York City....
Aug 23, 2016 08:11 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sorrento Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, Aug. 23, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sorrento Therapeutics, Inc. (NASDAQ: SRNE). ...
Aug 15, 2016 07:34 pm ET
Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline
SAN DIEGO, Aug. 15, 2016 /PRNewswire/ -- Scintilla Pharmaceuticals, Inc. ("Scintilla"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has entered into a binding term sheet to acquire Semnur Pharmaceuticals, Inc. ("Semnur"). Scintilla's lead program is resiniferatoxin ("RTX") for the treatment of intractable cancer pain....
Aug 15, 2016 10:00 am ET
Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development
SAN DIEGO, Aug. 15, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; "Celgene"), has been appointed to the position of Chief Medical Officer and President of Clinical Development....
Aug 09, 2016 10:20 am ET
Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc.
Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced the successful completion of a $1,150,000 financing transaction led by an investment from Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
Aug 08, 2016 10:00 am ET
Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals to Add a Late-Stage Asset to Bolster its Pain Management Business
SAN DIEGO, Aug. 8, 2016 /PRNewswire/ -- Scintilla Pharmaceuticals, Inc. ("Scintilla"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has entered into a binding term sheet to acquire SCILEX Pharmaceuticals, Inc. ("SCILEX"). Scintilla's lead program is resiniferatoxin ("RTX") for the treatment of intractable cancer pain. ...
Aug 02, 2016 10:00 am ET
Sorrento to Form Joint Venture with CHA Biotech to Develop and Commercialize Natural Killer Cell Therapies
SAN DIEGO, Aug. 2, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has entered into a binding term sheet to create a joint venture  ("JV") with CHA Biotech Co. , LTD,  (KOSDAQ: CHA; "CBT") of South Korea to develop and commercialize proprietary Chimeric Antigen Receptor ("CAR") modified cellular therapies based on CBT's Activated Killer Cell ("AKC") technology and five of  Sorrento's CARs for all disease conditi...
Aug 01, 2016 08:00 am ET
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
SAN DIEGO, Aug. 1, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today the appointment of Yue Alexander Wu, Ph.D to its Board of Directors (the "Board"). Dr. Wu will also serve as a member of the Compensation Committee and Audit Committee of the Board.  Doug Ebersole has resigned as a member of the Board for personal reasons....
Jul 11, 2016 10:00 am ET
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
SAN DIEGO, July 11, 2016 /CNW/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Servier, the largest non-listed pharmaceutical company in France, today announced a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento's fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110....
Jul 11, 2016 10:00 am ET
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
SAN DIEGO, July 11, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Servier, the largest non-listed pharmaceutical company in France, today announced a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento's fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110....
Jun 08, 2016 08:00 am ET
Sorrento Closes $150 Million Private Placement Investments
SAN DIEGO, June 8, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs announced today that it has closed on $150 million related to the private placements of common stock and warrants previously announced by the company on April 4, 2016.  ...
Jun 07, 2016 10:04 am ET
Sorrento and 3SBio Announce CAR-T Joint Venture in China
SAN DIEGO, June 7, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today its subsidiary TNK Therapeutics, Inc. ("TNK") has entered into a joint venture agreement ("JVA") with Shenyang Sunshine Pharmaceutical Company Ltd ("3SBio") to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's chimeric antigen receptor T cell ("CAR-T")  technology targeting carcinoembryonic a...
May 26, 2016 08:00 am ET
Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference
SAN DIEGO, May 26, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that Dr. Henry Ji, President and CEO, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York, NY.  The Sorrento presentation is scheduled to begin at 9:00am EDT.  ...
May 16, 2016 08:00 am ET
Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody
SAN DIEGO, May 16, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new therapies for cancer and other unmet medical needs announced that its partner, Mabtech Ltd., has successfully completed a combined Phase 2 & 3 clinical study in China for STI-004, a biosimilar antibody for Omalizumab (Xolair®). STI-004 met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled clinical trial....
May 09, 2016 01:32 pm ET
Sorrento Therapeutics engaged advisors for exploring strategic alternatives
SAN DIEGO, May 9, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that early this year it engaged financial advisors to assist the company in exploring and evaluating strategic alternatives to maximize shareholder value....
May 06, 2016 10:00 am ET
Wildcat Capital Issues Letter to Board of Sorrento Therapeutics
NEW YORK, May 6, 2016 /PRNewswire/ -- Wildcat Capital Management LLC ("Wildcat"), whose clients hold an ownership stake of 6.5% of the common stock of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (the "Company" or "Sorrento"), today sent a letter to the Company's Board of Directors (the "Board") urging the Board to take specific actions to remedy the ongoing destruction of significant shareholder value.  In particular, the letter calls for the Board to immediately terminate and replace Dr. Henry Ji as Chief Executive Officer and to stop recently announced financing transactions to avoid furthe...
May 02, 2016 12:24 pm ET
Sorrento closes private placement with Yuhan Corporation
SAN DIEGO, May 2, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has closed its previously announced private placement of common stock and warrants with Yuhan Corporation (000100.KS; "Yuhan") of South Korea for gross proceeds of $10 million....
May 02, 2016 08:00 am ET
Sorrento to Present at 2 Upcoming Conferences in New York City
SAN DIEGO, May 2, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at 2 upcoming conferences in New York City:...
Apr 14, 2016 08:00 am ET
Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, April 14, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 - 20, 2016....
Apr 06, 2016 01:53 pm ET
Sorrento to Present at the Jefferies Immuno-Oncology Summit
SAN DIEGO, April 6, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at the Jefferies Immuno-Oncology Summit on Thursday, April 7, 2016 from 7:55 am to 8:20 am EDT. The conference will take place at the Boston Harbor Hotel in Boston, MA....
Apr 05, 2016 07:42 pm ET
Sorrento Appoints Kevin M. Herde As Chief Financial Officer
SAN DIEGO, April 5, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today announced that Kevin M. Herde has been appointed to the position of Executive Vice President & Chief Financial Officer. ...
Apr 04, 2016 09:22 pm ET
Sorrento Announces Definitive Agreements for up to $150 Million Private Placement
SAN DIEGO, April 4, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs company, today announced that it has entered into definitive agreements with institutional investors and its strategic corporate partner, Yuhan Corporation (000100.KS; Yuhan) of South Korea, whereby such investors will invest up to approximately $150 million in separate private placements in newly issued common stock (the "Shares") at $5.55 per share and receive warrants to purchas...
Mar 14, 2016 08:00 am ET
Sorrento to Present at the 28th Annual ROTH Conference
SAN DIEGO, March 14, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Henry Ji, Ph.D., Chairman and CEO, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 from 7:00 am to 7:30 am PDT in Salon 6 - Yellow. The conference will take place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA....
Mar 04, 2016 07:00 am ET
Sorrento to Present at the Cowen and Company 36th Annual Health Care Conference
SAN DIEGO, March 4, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Henry Ji, Ph.D., President and CEO, will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 from 10:00 am to 10:30 am EST in the Harvard room, 3rd Floor (breakout 10:40-11:10 AM  in Brandeis, 3rd Floor). The conference will take place at the Boston Marriott Copley Place in Boston, MA....
Mar 02, 2016 07:00 am ET
Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia
SAN DIEGO and SEOUL, South Korea, March 2, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Yuhan Corporation (000100.KS; Yuhan), one of the largest and most respected pharmaceutical companies in South Korea, today announced that they have entered into an agreement to form a joint venture company (JVC),  ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for...